<DOC>
	<DOCNO>NCT00000999</DOCNO>
	<brief_summary>To obtain information long-term safety toxicity zidovudine ( AZT ) . To ascertain whether interruption/resumption low dosage optimal management AZT toxicity . Because high incidence toxicity relatively short-term follow-up patient due early end Phase II placebo-controlled experiment , valuable continue get information long-term toxicity AZT .</brief_summary>
	<brief_title>The Safety Effectiveness Zidovudine ( AZT ) Treatment HIV Infection Patients With AIDS Advanced ARC</brief_title>
	<detailed_description>Because high incidence toxicity relatively short-term follow-up patient due early end Phase II placebo-controlled experiment , valuable continue get information long-term toxicity AZT . This study provide AZT 6 month AIDS patient previously enrol AZT Treatment IND protocol patient qualify AZT drug labeling . Patients randomize 1 2 regimen management toxicity .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : For fever control mild analgesia , modest dos aspirin nonprescription dos ibuprofen may use caution ; prolong ( &gt; 72 hour ) administration advise without dose supervision . Patients must document history positive HIV antibody ELISA , positive result ELISA study entry one follow category : AIDS patient recover one episodes categorically confirm Pneumocystis carinii pneumonia ( PCP ) previously enrol zidovudine ( AZT ) treatment IND protocol . Patients qualify AZT labeling : ( ) patient prior episode cytologically confirm PCP ; ( b ) patient prior episode AIDS defining opportunistic infection &lt; 200 T4 cell ; ( c ) patient advanced AIDS relate complex ( ARC ) define clinical diagnosis mucocutaneous candidiasis and/or unexplained weight loss ( = &gt; 15 lbs &gt; 10 percent total body weight within previous 3 month ) &lt; 200 T4 cell one follow symptom : ( 1 ) fever &gt; 100 degree F without infectious cause &gt; 3 week duration ; ( 2 ) clinical diagnosis hairy leukoplakia ; ( 3 ) herpes zoster infection within 3 month entry ; ( 4 ) unexplained diarrhea 3 sample eliminate ovum , parasite , cryptosporidia , Mycobacterium aviumintracellulare . Note : Kaposi 's sarcoma without symptom list , regardless total T4 lymphocyte count , constitute indication AZT treatment label . Exclusion Criteria Coexisting Condition : Patients whose symptom fit category describe Disease Status General Inclusion Criteria exclude . Concurrent Medication : Excluded : Acetaminophen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>